Toronto, Ontario / ACCESSWIRE / May 29, 2014 / Theralase Technologies Inc.
("Theralase") (TSXV: TLT)
(TLTFF: OTCBB) announced today that in preclinical
animal testing, performed at Princess Margaret Cancer
Centre, University Health Network ("UHN"), it has
discovered that its lead Photo Dynamic Compound (PDC), intended for
the destruction of cancer, has demonstrated an ability to render
animals immune to repeated exposures of the same cancer.
This initial data has been
accepted for presentation at the 37th
Annual American Society for Photobiology taking place in San
Diego, California in June 2014.
In previous research conducted
at UHN by Theralase, mice were injected
with 350,000 colon cancer cells (murine cell line CT26.CL25) to
produce tumours that were allowed to grow to approximately five
millimeters in size. They were treated with an intra-tumoural
injection of Theralase's lead PDC (3
mg/kg TLDOsH2IP) and then illuminated by Near Infrared (NIR) light
(808 nm, 600 J cm-2) to activate the PDC. The vast majority of
tumours were completely destroyed, with the PDC treatment
demonstrating prolonged tumour regression.
In this latest
research, the same mice who received the
initial, successful Photo Dynamic Therapy (PDT) were
re-injected with the same number of colon cancer cells, 13 to 23
days later. With no further treatment intervention,
mice in these experiments, demonstrated either a small
tumour regrowth, which quickly regressed, or in the majority of
animals, no tumour regrowth at all, suggesting a short-term
immune-mediated (immune "memory response") tumour
rejection.
To further prove the
resilience of the PDT treatment, these same animals were then
injected a third time with an additional 350,000 colon cancer cells
at ten months post PDT treatment. None of these
animals showed any sign of tumour regrowth, even at 3
months post follow up, suggesting the presence of a long-term
anti-tumour immunity, responsible for complete tumour
rejection.
To strengthen the data,
control experiments were conducted where age matched mice without
prior tumour exposure or PDT treatment were injected with the same
number of colon cancer cells, where the majority of these mice
proceeded to develop tumours and did not survive more than 1 month
following the injection.
These
initial results are now being further researched by
Theralase and UHN scientists to confirm the immune-mediated (immune "memory response") tumour
rejection in additional subject animals. This potential short term
and long term anti-cancer memory response suggests a major
breakthrough in cancer research and may provide substantial
treatment benefit and survival advantage to cancer patients.
Technology that is able to rapidly and effectively destroy
"patient-specific" cancer cells, prevent their recurrence and
provide long lasting protection against local and distant
metastasis, offers immense clinical benefit to cancer
patients and the facilities that treat their disease.
Dr. Arkady Mandel, Chief
Scientific Officer of Theralase stated, "This is one of the first preclinical trials to show
that it's possible to generate a long-term anticancer memory
response. For the first time in our research program,
we have demonstrated that NIR PDT leads not only to long standing
clearance of colon cancer cells, but also
provides long lasting protection against further tumour cell
challenge in young (eight to ten weeks old) and older (ten to
eleven month old) mice. It is our first step toward the long-term goal of
developing an affordable and practical vaccine to prevent cancer
recurrence. The next steps are to further validate this research
with additional animals and then find the best way of translating
this research into a human clinical trial. To complete our
preclinical and clinical development in this ground breaking work,
we are collaborating with experts in medical biophysics, immunology
and clinical oncology at UHN and
with other internationally acclaimed clinical research institutes
to further advance this remarkable platform technology."
Dr. Lothar Lilge PhD,
Professor in the Department of Medical Biophysics at the University
of Toronto, Senior Scientist, Princess Margaret Cancer Centre,
University Health Network stated that, "We are
delighted that we were able to partner in the preclinical research
for this ground breaking discovery. The ability to effectively
destroy cancer and simultaneously stimulate the immune system to
target micro metastasis beyond the initial treatment volume is
necessary to provide long term disease control. We will now proceed
to confirm these findings for a range of induced and spontaneous
animal tumour models."
Dr. Michael Jewett MD,
clinician investigator and uro-oncologist at UHN stated, "I am
excited about the possibilities of this discovery. If this newly
discovered characteristic of the Theralase PDCs can be replicated
in humans and demonstrate the same efficacy that it has in small
animals, then the implications to the war on cancer could be
immense. I look forward to furthering this preclinical work to the
clinical stage to validate its efficacy in humans."
Roger Dumoulin-White,
President and CEO of Theralase stated that, "If our PDC technology
is proven effective in cancer patients, the implications of this
discovery are nothing short of game changing for both Theralase and
for cancer patients. The ability to destroy the original cancer and
also program the body's immune system to prevent its recurrence,
after only a single treatment, is nothing short of miraculous. Born
a technical person at heart, I have always marvelled at the
complexity of the human body and regarded it as the single most
complex and intricate machine ever devised. The opportunity to
bring technology to market that could help preserve the integrity
of the human body and destroy such a deadly disease as cancer,
fills me with hope and a great sense of accomplishment. The
scientific, clinical and engineering teams at UHN, Acadia and
Theralase are all fully dedicated to bringing the Theralase
anti-cancer PDC technology to the forefront of clinical success, as
soon as possible, in order to help eradicate the world of cancer
and assist cancer patients stricken with this deadly
disease."
About Theralase Technologies Inc.
Theralase Technologies Inc. designs,
manufactures and markets patented, superpulsed laser technology
used in eliminating pain and destroying cancer. Theralase
technology is safe and effective in eliminating pain, reducing
inflammation and accelerating tissue regeneration of numerous
nerve, muscle and joint conditions. Theralase is actively
developing patented technology that is able to target and destroy
cancers, bacteria and viruses when light activated.
Additional information is
available at www.theralase.com and
www.sedar.com .
This press release contains
forward-looking statements, which reflect the Company's current
expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could
differ materially from those projected herein. The Company
disclaims any obligation to update these forward-looking
statements.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchanges) accepts responsibility for
the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO, Theralase Technologies
Inc.
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com
SOURCE: Theralase Technologies Inc.
Theralase Technologies (TSXV:TLT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Theralase Technologies (TSXV:TLT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024